Table: Aska Pharmaceutical Holdings -Q1 group results
Aug 4 (Reuters)-
Aska Pharmaceutical Holdings Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2025 Jun 30, 2024 Mar 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 19.32 16.35 75.00
(+18.2 pct) (+2.1 pct) (+16.9 pct)
Operating 1.48 1.76 6.80
(-15.9 pct) (+3.1 pct) (+27.5 pct)
Recurring 1.62 1.81 6.80
(-10.6 pct) (+0.2 pct) (+33.1 pct)
Net 1.24 1.27 5.20
(-2.3 pct) (-10.9 pct) (+1.9 pct)
EPS 43.88 yen 44.95 yen 183.44 yen
Ann Div 55.00 yen 55.00 yen
-Q2 div 25.00 yen 27.00 yen
-Q4 div 30.00 yen 28.00 yen
NOTE - Aska Pharmaceutical Holdings Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T
Recent news on ASKA Pharmaceutical Holdings
See all newsTable: Aska Pharmaceutical Holdings -Q1 group results
Brief: Dalton Investment Strongly Oppose Conditional Activation Of Countermeasures Announced By Aska Pharmaceutical Holdings On May 25
Brief: Aska Pharmaceutical -Plan To Put To Shareholders Proposal On Countermeasures Against Potential Large-Scale Share Purchase By Dalton And Related Parties
Table: Aska Pharmaceutical Holdings -2025/26 group results
Table: Aska Pharmaceutical Holdings -2025/26 group results